Phathom Pharmaceuticals Inc’s recently made public that its Chief Operating Officer Nabulsi Azmi unloaded Company’s shares for reported $8944.0 on Dec 19 ’24. In the deal valued at $8.00 per share,1,118 shares were sold. As a result of this transaction, Nabulsi Azmi now holds 239,303 shares worth roughly $1.62 million.
Then, Henderson Molly sold 1,291 shares, generating $10,328 in total proceeds. Upon selling the shares at $8.00, the CFO and CBO now owns 98,156 shares.
Before that, KARBE FRANK bought 12,500 shares. Phathom Pharmaceuticals Inc shares valued at $99,084 were divested by the Director at a price of $7.93 per share. As a result of the transaction, KARBE FRANK now holds 57,000 shares, worth roughly $0.39 million.
Stifel initiated its Phathom Pharmaceuticals Inc [PHAT] rating to a Buy in a research note published on May 03, 2024; the price target was $24. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early January has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright began covering PHAT with “Buy” recommendation on August 09, 2023. Evercore ISI revised its rating on May 11, 2023. It rated PHAT as “an Outperform” which previously was an “an In-line”.
Price Performance Review of PHAT
On Tuesday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock jump 2.57% to $6.79. Over the last five days, the stock has lost -10.78%. Phathom Pharmaceuticals Inc shares have fallen nearly -16.38% since the year began. Nevertheless, the stocks have fallen -11.59% over the past one year. While a 52-week high of $19.71 was reached on 01/02/25, a 52-week low of $6.07 was recorded on 01/13/25. SMA at 50 days reached $9.78, while 200 days put it at $12.02.
Levels Of Support And Resistance For PHAT Stock
The 24-hour chart illustrates a support level at 6.53, which if violated will result in even more drops to 6.27. On the upside, there is a resistance level at 6.94. A further resistance level may holdings at 7.09. The Relative Strength Index (RSI) on the 14-day chart is 33.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.69, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.09%. Stochastics %K at 16.10% indicates the stock is a buying.
How much short interest is there in Phathom Pharmaceuticals Inc?
A steep rise in short interest was recorded in Phathom Pharmaceuticals Inc stocks on 2024-12-31, growing by 0.9 million shares to a total of 14.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 14.05 million shares. There was a rise of 6.02%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 13, 2023 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.
